Vaccine developer Janssen is considering closing its factory in the Swiss capital Bern. On Tuesday it opened a consultation procedure with employees to find alternatives. Up to 300 employees could be affected by a plant closure. +Get the most important news from Switzerland in your inbox The subsidiary of US pharmaceutical giant Johnson & Johnson said on Tuesday that it was considering closing the Bern plant for two reasons. Firstly, a new vaccine designed to prevent colibacillus infections is not as effective as hoped. Secondly, the production of lentiviral vectors will soon cease in Bern. The global company Johnson & Johnson is about to inaugurate a new, much larger plant in the Netherlands, according to a press release. The factory that houses Janssen’s operations in Bern has a long history. It was founded in 1898 as the Swiss Institute of Serotherapy and Vaccination. Translated from German by DeepL/jdp How we work We select the most relevant news for an international audience …